Ferroptosis-related biotargets and network mechanisms of fucoidan against colorectal cancer: An integrated bioinformatic and experimental approach

Jiaqi Liu, Yuexia Meng, Bihui Li, Pin Wang, Xiaowei Wan, Wenjun Huang, Rong Li
In: International Journal of Biological Macromolecules · 2022 · vol. 222(Pt A) , pp. 1522–1530 · doi:10.1016/j.ijbiomac.2022.09.255 · PMID:36195230 · W4300166994
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This study integrates bioinformatic and experimental approaches to identify ferroptosis-related biotargets and elucidate the network mechanisms through which fucoidan exerts anti-colorectal cancer effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Ferroptosis, a type of iron-dependent cell death, has been linked with the occurrence and progression of malignant tumors, including colorectal cancer (CRC). Fucoidan, an algal fucose-rich molecule, has been discovered preclinically to have an anti-CRC signature. Although some underlying mechanisms are reported, many signaling pathways associated with ferroptosis in fucoidan treatment of CRC are still unidentified. In this study, we applied network pharmacology and molecular docking technologies to unmask and identify the medication targets and pharmaceutical mechanisms involved in ferroptosis in fucoidan-treated CRC. 19 ferroptosis-related core targets were identified and enrichment analysis indicated their contribution to pharmacological actions and mechanisms in fucoidan treatment of CRC, including ferroptosis-related signaling pathways. Additional molecular docking verification confirmed that fucoidan docked well with ranked core targets, including transcription factor p65 (RELA), interleukin-1 beta (IL1B), and interleukin-6 (IL6). These in silico findings were validated experimentally in CRC cells following fucoidan treatment. RELA, IL1B, and IL6 expressed positively in human CRC samples. In conclusion, the pharmacological mechanisms of fucoidan in treating CRC may be achieved through multiple biological targets and multiple molecular pathways associated with ferroptosis. Thus, these preclinical findings have laid a theoretical foundation for further research and clinical treatment of CRC using fucoidan.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (55)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK